Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 7/20 | 0.41 |
| ▸ | F2 | P00734 | 3/20 | 0.41 |
| ▸ | CTSG | P08311 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20701800 | 1.00 | FAAH (0.48) | FAAHNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL17481627 | 0.89 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2GAAMAPK1 | |
| SCHEMBL1929718 | 0.83 | HTR2C (0.48) | NPC1RAB9ASMN1; SMN2GAAMAPK1 | |
| SCHEMBL20701414 | 0.83 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2GAAMAPK1 | |
| SCHEMBL22927031 | 0.78 | TSHR (0.46) | NPC1RAB9ASMN1; SMN2GAAMAPK1 | |
| SCHEMBL14554566 | 0.77 | FAAH (0.50) | FAAHNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL8978249 | 0.75 | HTR2C (0.56) | NPC1RAB9ASMN1; SMN2GAAMAPK1 | |
| SCHEMBL6173741 | 0.74 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2GAAMAPK1 | |
| SCHEMBL14554771 | 0.74 | SMN1; SMN2 (0.62) | NPC1RAB9ASMN1; SMN2ELANEF2 | |
| SCHEMBL1710024 | 0.73 | TSHR (0.52) | HTR2CL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186270-B1 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC (CA) | 2020-02-19 | — | — | EP | disclosed |
| US-10537652-B2 | Cyclic urea compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2020-01-21 | — | — | US | disclosed |
| US-20190151484-A2 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2019-05-23 | — | — | US | disclosed |
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | VIDA THERAPEUTICS, INC. (CA) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | GZMB, CTSB, SERPINB1 | FAAH 1543/4885NPC1 2214/4885RAB9A 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.